Skip to content
10-Q

Quarterly Report

THESEUS PHARMACEUTICALS, INC.

0001745020-23-000009

← back to feed
Filed
May 11, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 5, 2023 43.58M sh
Shares Diluted Q1 2023 · Mar 31, 2023 42.37M sh
Shares Diluted Q1 2023 · Mar 31, 2022 38.25M sh
Capex Q1 2023 · Mar 31, 2023 $0
Capex Q1 2023 · Mar 31, 2022 $27K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$18.63M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$7.68M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $109.7M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $94.61M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $146.28M
Stockholders Equity Q1 2023 · Mar 31, 2023 $245.49M
Stockholders Equity Q1 2023 · Dec 31, 2022 $207.62M
Stockholders Equity Q1 2023 · Mar 31, 2022 $237.85M
Stockholders Equity Q1 2023 · Dec 31, 2021 $246.43M
Current Liabilities Q1 2023 · Mar 31, 2023 $6.62M
Current Liabilities Q1 2023 · Dec 31, 2022 $11.13M
Total Liabilities Q1 2023 · Mar 31, 2023 $10.13M
Total Liabilities Q1 2023 · Dec 31, 2022 $14.83M
Current Assets Q1 2023 · Mar 31, 2023 $242.4M
Current Assets Q1 2023 · Dec 31, 2022 $202.12M
Total Assets Q1 2023 · Mar 31, 2023 $255.62M
Total Assets Q1 2023 · Dec 31, 2022 $222.45M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.34
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.27
Eps Basic Q1 2023 · Mar 31, 2023 −$0.34
Eps Basic Q1 2023 · Mar 31, 2022 −$0.27
Sga Expense Q1 2023 · Mar 31, 2023 $4.65M
Sga Expense Q1 2023 · Mar 31, 2022 $4.03M
Rd Expense Q1 2023 · Mar 31, 2023 $12.4M
Rd Expense Q1 2023 · Mar 31, 2022 $6.55M
Net Income Q1 2023 · Mar 31, 2023 −$14.59M
Net Income Q1 2023 · Mar 31, 2022 −$10.5M
Operating Income Q1 2023 · Mar 31, 2023 −$17.06M
Operating Income Q1 2023 · Mar 31, 2022 −$10.58M